Your AI-Trained Oncology Knowledge Connection!
C. Ola Landgren, MD, PhD, discusses progression-free survival data from the phase 3 DETERMINATION trial examining lenalidomide, bortezomib, and dexamethasone with or without autologous stem cell transplant plus continuous lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Mark Pegram, MD, discussed the highlights from ASCO 2022, regarding antibody drug conjugates.
The FDA has allowed the phase 3 FLAMINGO-01 trial assessing GLSI-100 in patients with HER2/Neu-positive breast cancer and HLA-A*02 positive to proceed following concerns related to the manufacturing and pharmacy process.
CV-01 delivery of sonodynamic therapy has been granted orphan drug designation and fast track designation by the FDA for the treatment of recurrent glioblastoma.
Kimberley R. Doucette, MD, MSC; and David H. Vesole, MD, PhD, discuss updates to frontline treatment in multiple myeloma.
Sarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.
Patients with ALK-positive inflammatory myofibroblastic tumors can now receive treatment with crizotinib following the agent’s approval by the FDA.
Several immune-related long noncoding RNA signatures—including PCAT19 and SCARNA9—may be associated with prognosis in patients with endometrial cancer, according to the new research.
The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.
Sheila Lahijani, MD, FACLP, gives her perspective on the need for psycho-oncologists to help patients during their cancer journeys.
Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.
At the 2022 American Society of Clinical Oncology Annual meeting, Robert H. Vonderheide, MD, DPhil, and colleagues from the Parker Institute for Cancer Immunotherapy present research into biosignatures of survival with different chemoimmunotherapy regimens for pancreatic ductal adenocarcinoma.
At 24 months of follow-up, MRI-guided focused ultrasound focal therapy was found to be safe and effective for patients with grade group 2 or 3 prostate cancer.
“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”
Kirk E. Cahill, MD, and Sonali M. Smith, MD, spoke with CancerNetwork® about their review of the current management and treatment of follicular lymphoma published in the journal ONCOLOGY®.
The FDA has accepted a biologics license application for vic-trastuzumab duocarmazine for patients with HER2-positive unresectable locally advanced or metastatic breast cancer.
The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.
In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.
At 2022 ASCO, Paul G. Richardson, MD, dives into results of the DETERMINATION study, which examined triplet therapy with lenalidomide plus either lenalidomide maintenance until progression or autologous stem transplantation in newly diagnosed multiple myeloma.
Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.
Patients with low-risk locoregionally advanced nasopharyngeal carcinoma who received 2 cycles of concurrent cisplatin plus intensity-modulated radiotherapy compared with 3 cycles had better survival and manageable toxicities.
The regulatory organization indicated that duvelisib induces increased risk of death or serious adverse effects in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
Those with non–small cell lung cancer who had increasing tumor mutational burden appeared to experience better inflammatory T-cell–mediated responses compared with those who had low tumor mutational burden.
Biagio Ricciuti, MD, spoke about results of pembrolizumab monotherapy administration in patients with non–small cell lung cancer who had a PD-L1 tumor proportion score of 90% or more.
The phase 2 CTMX-2009-002 trial met its primary end point of confirmed objective response greater than 10% for patients with hormone receptor–positive, HER2–non-amplified breast cancer being treated with praluzatamab ravtansine.
Saad Z. Usmani, MD, MBA, FACP, discusses the use of lenalidomide, bortezomib, and dexamethasone with or without elotuzumab for newly diagnosed, high-risk multiple myeloma.
Ola Landgren, MD, PhD, highlights how future research efforts in multiple myeloma are likely to focus on chemotherapy-free regimens and minimal residual disease detection.
Enzalutamide monotherapy could be a promising alternative to active surveillance for patients with low- and intermediate-risk localized prostate cancer.
After receipt of a complete response letter in May 2022, a biologics license application for toripalimab monotherapy in the second line or later following platinum chemotherapy or in combination with chemotherapy in the first-line setting for advanced recurrent or metastatic nasopharyngeal carcinoma was resubmitted to and accepted by the FDA.
